News

Sinobiopharma has acquired rights to the following patents – Synthesis of amantadine hydrochloride, method for preparation of 17-acylsinomenine derivatives, preparation of 17-sulfonylsinomenine, preparation of N-substituted sinomenine, method for

Diagnostics to rapidly screen individual patients for influenza virus in hospitals, clinics and doctors’ offices, personal protection devices such as facemasks to help stop the spread of disease,

The company has reported net revenues of $10.9 billion for the first quarter of 2009, a decrease of 8%, compared to $11.85 billion for the first quarter of

Net revenue for the fourth quarter of 2008 was $7.06 million, a decrease of 14.5% from $8.32 million for the fourth quarter of 2007. The decrease in net

The main items in the report are: Highlights Operating profit improved by NOK16.7 million to NOK-5.7 million (NOK-22.5 million) Liquid funds amounted to NOK161.9 million at the end

Before joining PerkinElmer, Wilson was the corporate vice president of investor relations at Danaher Corporation (Danaher). At Danaher, he held key financial and business management positions. Wilson comes

“Rob’s leadership and deep understanding of PerkinElmer’s businesses, organization and entrepreneurial culture makes him ideally suited to lead the Company going forward,” said Summe. “I believe that PerkinElmer

Second Quarter Summary: Financial highlights: Operating income of $6.2 million Revenue by market: Therapeutic: Cardiovascular – $9.6 million Ophthalmology – $3.7 million Other Markets – $2.9 million Diagnostic

Scott Garrett, chairman, president and chief executive officer, said, Approximately 80% of our revenue is recurring, which continued to grow at 5% on a constant currency basis giving